.Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EX06_Omidenepag.Omidenepag .Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EX06_Omidenepag.Omidenepag| name: | Omidenepag |
| ATC code: | S01EX06 | route: | ophthalmic |
| n-compartments | 1 |
Omidenepag isopropyl is a selective prostaglandin E2 receptor agonist used as an ophthalmic solution to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first approved in Japan and has gained some approvals in other countries.
No published studies have been found describing detailed human pharmacokinetic parameters for omidenepag after ophthalmic administration. Estimates are based on available product characteristics and pharmacological class properties.
Aihara, M, et al., & Shams, NK (2019). Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 35(10) 542–550. DOI:10.1089/jop.2019.0044 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31674861